Faculty
 

Deborah Donnell, Ph.D.

Dr. Deborah Donnell is a Principal Staff Scientist in the Vaccine and Infectious Disease Institute (VIDI). She is the Principal Investigator of the HIV Prevention Trials Network Statistical and Data Management Center. The scientific faculty, drawing from the University of Washington Biostatistics department and the Population Sciences Program in VIDI, are responsible for the design and analysis of Phase III clinical trials to access the efficacy of biomedical and behavioral interventions to prevent the transmission of HIV. She currently has the lead statistician role in several ongoing trials, including:

  • HPTN058: A Phase III randomized controlled trial to evaluate the efficacy of drug treatment in prevention of HIV infection and death among opiate dependent injection
  • HPTN065 TLC-Plus: A Study to Evaluate the Feasibility of an Enhanced Test, Link to Care, Plus Treat Approach for HIV Prevention in the United States

In addition, Dr. Donnell is an investigator with the International Clinical Research Center in the Global Health Department at the University of Washington, where she leads the analytic team engaged in international Phase III clinical trials for the prevention of HIV. She is the lead statistician on the Bill and Melinda Gates Funded Partners PrEP Trial: Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples.

Dr. Donnell has been engaged in HIV prevention research since 1993, and has extensive management and scientific expertise.  Her research interests include: Conduct, Design and Monitoring of Randomized Clinical Trials;  Analysis of complex behavioral and adherence data and application to efficacy and effectiveness; Use and applications of surveillance data to HIV prevention research.

Recent Publications:
1. Chesney M, Donnell D, Seage G, Bryant K. Project Explore: Impact of Alcohol Use on Hiv Sero-Incidence among High-Risk Msm in a Large-Scale Prospective Preventive Intervention. Alcoholism-Clinical and Experimental Research. Jun 2009;33(6):41a-41a.
2. Church JD, Mwatha A, Bagenda D, et al. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses. Jul 2009;25(7):673-677.
3. Hudelson SE, Marlowe N, Huang W, et al. Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors. AIDS Res Hum Retroviruses. Jul 2009;25(7):701-705.
4. Latkin C, Donnell D, Celentano DD, et al. Relationships between social norms, social network characteristics, and HIV risk behaviors in Thailand and the United States. Health Psychol. May 2009;28(3):323-329.
5. Latkin CA, Donnell D, Metzger D, et al. The efficacy of a network intervention to reduce HIV risk behaviors among drug users and risk partners in Chiang Mai, Thailand and Philadelphia, USA. Soc Sci Med. Feb 2009;68(4):740-748.
6. Mimiaga MJ, Noonan E, Donnell D, et al. Childhood sexual abuse is highly associated with HIV risk-taking behavior and infection among MSM in the EXPLORE Study. J Acquir Immune Defic Syndr. Jul 1 2009;51(3):340-348.
7. Mmiro FA, Aizire J, Mwatha AK, et al. Predictors of Early and Late Mother-to-Child Transmission of HIV in a Breastfeeding Population: HIV Network for Prevention Trials 012 Experience, Kampala, Uganda. J Acquir Immune Defic Syndr. Jul 16 2009.
8. Church JD, Mwatha A, Bagenda D, et al. In utero HIV infection is associated with an increased risk of nevirapine resistance in Ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res and Human Retroviruses. (In Press).
9. Baeten JM, Donnell D, Kapiga SH, et al. Male circumcision and risk of male-to-female HIV-1 transmission: a multinational prospective study in African HIV-1-serodiscordant couples. AIDS. Dec 29 2009.
10. Donnell DJ, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis, Lancet (in Press).